Sanofi-Aventis SA has obtained regulatory approval for the use of its drug Taxotere to treat advanced head and neck cancer in patients who are about to undergo chemoradiotherapy and surgery. The FDA approval follows clinical results showing that the drug improved patient survival rate by more than three years when combined with standard chemotherapy.

Related Summaries